Skip to content
2000
Volume 17, Issue 29
  • ISSN: 0929-8673
  • E-ISSN: 1875-533X

Abstract

Cancer immunotherapy with interleukin-2 (IL-2) has demonstrated long term disease control in metastatic renal cell carcinoma and malignant melanoma. With introduction of novel kinase inhibitors, immunomodulatory molecules, cytokines, and vaccines for treatment of cancer there is an increased interest in combining these therapeutic strategies with IL-2. Here we discuss toxicity and established activity of IL-2 in the management of advanced malignancies, and speculate on future use of this cytokine for treatment of cancer.

Loading

Article metrics loading...

/content/journals/cmc/10.2174/092986710793176410
2010-01-01
2025-04-21
Loading full text...

Full text loading...

/content/journals/cmc/10.2174/092986710793176410
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test